| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin A1c at 24 Weeks, Changes from baseline in HbA1c in placebo and treatment group at end of 24 weeks treatment, Baseline and Week 24 | Secondary: Changes in Systolic and Diastolic Blood Pressure at Week 24, Changes from baseline in systolic and diastolic blood pressure in placebo and treatment group after 24 weeks of treatment, Baseline and Week 24|Changes in Body Weight at Week 24, Changes from baseline in body weight in placebo and treatment group after 24 weeks of treatment, Baseline and week 24|Change From Baseline in HbA1c Over 96 Weeks Time, Change from baseline in HbA1c level over 96 weeks in placebo and treatment group. The treatment group was treated with EGT0001442 for 24 weeks., Baseline and up to 96 weeks|Change From Baseline Over Time in Fasting Plasma Glucose (FPG), Changes from baseline in FPG in placebo and treatment group over 24 weeks of treatment, 24 weeks|Percentage of Subjects Achieving HbA1c <7%, The number and percentage of subjects achieving HbA1c response levels \<7% for the FAS using LOCF is reported, Baseline and up to 96 weeks
|
| Locations: |
Site 5, Buena Park, California, United States|Site 4, Los Angeles, California, United States|Site 3, Santa Ana, California, United States|Site 1, Hialeah, Florida, United States|Site 9, Berlin, New Jersey, United States|Site 7, Cary, North Carolina, United States|Site 6, Marion, Ohio, United States|Site 8, Munroe Falls, Ohio, United States|Site 2, Portland, Oregon, United States|Site 11, North Richland Hills, Texas, United States|Site 7, San Antonio, Texas, United States
|
